Exosomal ANXA1 derived from thyroid cancer cells is associated with malignant transformation of human thyroid follicular epithelial cells by promoting cell proliferation


Posted: 2021-11-15 20:00:00
Exosomes are nano‑sized extracellular vesicles that can be released from cancer cells. It has been shown that cancer cell‑derived exosomes may be associated with carcinogenesis by transferring signaling proteins from malignant to neighboring non‑malignant cells. In addition, annexin A1 (ANXA1) is a well‑known oncogene, that can be released from extracellular vesicles by cancer cells. However, the role of exosomal ANXA1 in the cell‑to‑cell communication of thyroid cancer and thyroid follicular epithelial cells remains unclear. In the present study, the protein expression levels of ANXA1 in thyroid cancer cells and thyroid cancer cell‑derived exosomes were analyzed using western blot analysis. In addition, Cell Counting Kit‑8 and Transwell assays were used to determine cell viability and invasion, respectively. The protein expression levels of ANXA1 were increased in thyroid cancer tissues and thyroid cancer cell lines. In addition, overexpression of ANXA1 significantly increased the proliferation and invasion of the SW579 cells, while knockdown of ANXA1 expression exerted the opposite results. Furthermore, ANXA1 was transferred from the SW579 cells to the Nthy‑ori3‑1 cells via exosomes. Exosomal ANXA1 markedly promoted the proliferation, invasion and epithelial‑to‑mesenchymal transition of the Nthy‑ori3‑1 cells. In addition, SW579 cell‑derived exosomal ANXA1 promoted tumor growth in a xenograft mouse model. Collectively, these findings indicated that SW579 cell‑derived exosomal ANXA1 promoted thyroid cancer development and Nthy‑ori3‑1 cell malignant transformation. Therefore, these findings may aid in the development of effective treatment methods for thyroid cancer. Keywords: annexin A1; exosome; malignant transformation; thyroid cancer.

参考サイト PubMed: exsome


Powered by Vergleichsportal


バイオクイックニュース日本語版:エクソソーム特集

バイオクイックニュース日本語版
2月 01, 2021 バイオアソシエイツ

カゼインを混合したエクソソームで効果が増強。筋ジストロフィーや心不全の治療に有望な可能性。

細胞由来の エクソソーム は、母乳中の主要なタンパク質(カゼイン)と混合して経口投与すると病気の治療に効果的であることが、シダーズ・サイナイ医療センター・シュミット心臓研究所の実験用マウスによる新研究で示された。2021年1月11日にJournal of Extracellular Vesiclesにオンラインで公開された調査結果は、筋ジストロフィーと心不全の患者を治療するための新しい経口薬を開発するための基礎を確立する可能性がある。…

ゲスト 699人 と メンバー 6人 がオンラインです